Catheter Precision announces accelerated momentum for LockeT device

Catheter Precision (VTAK) announced a surge in hospital evaluations and approvals for its LockeT suture retention device. As the company enters the first quarter of 2026, it reports significant progress in domestic and international product adoption, driven by successful clinical outcomes and the device’s ability to streamline hospital workflows. Following its highest recorded revenue for the month of January, and following its recent entry into several international markets, Catheter Precision has secured approval for evaluations at several additional influential high-volume centers throughout the Unites States. These evaluations are a critical precursor to long-term purchasing agreements, allowing clinical teams to validate LockeT’s efficacy and additional adoption at affiliated hospitals within a network.